Effective control of bone pain by octreotide in a patient with metastatic gastrinoma.
Burgess
J R
JR
Department of Diabetes and Endocrine Services, Royal Hobart Hospital, TAS.
Shepherd
J J
JJ
Murton
F J
FJ
Parameswaran
V
V
Greenaway
T M
TM
D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000556:secondary*; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D015408:Gastrinoma / Q000556:secondary*; D006728:Hormones / Q000627:therapeutic use*; D006801:Humans; D008113:Liver Neoplasms / Q000556:secondary; D008875:Middle Aged; D018761:Multiple Endocrine Neoplasia Type 1 / Q000473:pathology / Q000628:therapy; D015282:Octreotide / Q000627:therapeutic use*; D010146:Pain / Q000188:drug therapy*; D010166:Palliative Care; D010190:Pancreatic Neoplasms / Q000473:pathology*
D018931:Antineoplastic Agents, Hormonal; D006728:Hormones; D015282:Octreotide